Overview: vWF Multimers TestIntroduction: The vWF Multimers Test analyzes von Willebrand factor multimers to diagnose von Willebrand disease, causing excessive bleeding, helping guide treatment. Affecting 1 in 10,000 people, von Willebrand disease poses diagnostic challenges due to variable severity. Following 2023 International Society on Thrombosis and Haemostasis (ISTH) guidelines, it uses electrophoresis for high accuracy, supporting coagulation screening. This test is vital for diagnosis, treatment planning, and improving outcomes in hematology.
Other Names: vWF Multimer Analysis Test, von Willebrand Factor Assay.
FDA Status: Laboratory-developed test (LDT), meeting coagulation standards for diagnostic reliability.
Historical Milestone: vWF multimers testing began in the 1970s with research by Ruggeri, who identified multimer patterns. Electrophoresis advancements by Bio-Rad improved detection, surpassing earlier immunoassays.
Purpose: Analyzes vWF multimer patterns to diagnose von Willebrand disease, guides replacement therapy, and evaluates patients with excessive bleeding, aiming to manage hemostasis.
Test Parameters: vWF multimer patterns
Pretest Condition: No special preparation required. Collect plasma. Report history of bleeding disorders.
Specimen: Plasma (NaCit, 2-4 mL); 2 mL plasma in Na Citrate tube. Transport in a biohazard container.
Sample Stability at Room Temperature: 4 hours
Sample Stability at Refrigeration: 24 hours
Sample Stability at Frozen: 1 month
Medical History: Document excessive bleeding. Include current medications or family history.
Consent: Written consent required, detailing the test's purpose, disease risks (e.g., hemorrhage), and sample collection risks.
Procedural Considerations: Uses electrophoresis to analyze multimers, requiring labs with specialized equipment. Results available in 3-5 days. Performed in labs with strict handling.
Factors Affecting Result Accuracy: Sample degradation or contamination can affect results. Medications may alter levels, requiring correlation.
Clinical Significance: Abnormal patterns suggest von Willebrand disease, guiding therapy. Early treatment might prevent bleeding, while untreated cases lead to complications. Normal patterns may require other tests.
Specialist Consultation: Consult a hematologist for interpretation.
Additional Supporting Tests: vWF antigen, factor VIII, or genetic testing to confirm diagnosis.
Test Limitations: Specific to multimers; correlation with clinical status needed. False results possible with technical errors.
References: ISTH Guidelines, 2023; Journal of Thrombosis and Haemostasis, Ruggeri ZM, 2022.
